• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Co-Diagnostics Inc.

    6/3/26 4:22:01 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care
    Get the next $CODX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Co-Diagnostics, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)




    189763204

    (CUSIP Number)
    05/28/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    189763204


    1Names of Reporting Persons

    JANE STREET GROUP, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    236,359.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    236,359.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    236,359.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.4 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP Number(s):
    189763204


    1Names of Reporting Persons

    Jane Street Capital, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    189,817.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    189,817.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    189,817.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.2 %
    12Type of Reporting Person (See Instructions)

    BD


    SCHEDULE 13G

    CUSIP Number(s):
    189763204


    1Names of Reporting Persons

    Jane Street Global Trading, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    46,542.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    46,542.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    46,542.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.3 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Co-Diagnostics, Inc.
    (b)Address of issuer's principal executive offices:

    2401 S FOOTHILL DRIVE, SUITE D, SALT LAKE CITY, UTAH, 84109.
    Item 2. 
    (a)Name of person filing:

    Jane Street Group, LLC; Jane Street Capital, LLC; Jane Street Global Trading, LLC
    (b)Address or principal business office or, if none, residence:

    Jane Street Group, LLC 250 Vesey Street 6th Floor New York, NY 10281 Jane Street Capital, LLC 250 Vesey Street 6th Floor New York, NY 10281 Jane Street Global Trading, LLC 250 Vesey Street 6th Floor New York, NY 10281
    (c)Citizenship:

    See Item 4 of Cover Page
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP Number(s):

    189763204
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    236,359.00
    (b)Percent of class:

    6.4%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    236,359.00

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    236,359.00

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    Subsidiary Jane Street Capital, LLC Jane Street Global Trading, LLC
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    JANE STREET GROUP, LLC
     
    Signature:/s/ Jeremy Kahn
    Name/Title:Jeremy Kahn (Authorized Signatory)
    Date:06/03/2026
     
    Jane Street Capital, LLC
     
    Signature:/s/ Jeremy Kahn
    Name/Title:Jeremy Kahn (Authorized Signatory)
    Date:06/03/2026
     
    Jane Street Global Trading, LLC
     
    Signature:/s/ Jeremy Kahn
    Name/Title:Jeremy Kahn (Authorized Signatory)
    Date:06/03/2026
    Get the next $CODX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CODX

    DatePrice TargetRatingAnalyst
    8/12/2022$5.00Buy → Neutral
    Sidoti
    12/29/2021$14.00Buy
    Sidoti
    11/12/2021$16.00 → $15.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CODX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Co-Diagnostics downgraded by Sidoti with a new price target

    Sidoti downgraded Co-Diagnostics from Buy to Neutral and set a new price target of $5.00

    8/12/22 9:07:51 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Sidoti initiated coverage on Co-Diagnostics with a new price target

    Sidoti initiated coverage of Co-Diagnostics with a rating of Buy and set a new price target of $14.00

    12/29/21 8:45:34 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    HC Wainwright & Co. reiterated coverage on Co-Diagnostics with a new price target

    HC Wainwright & Co. reiterated coverage of Co-Diagnostics with a rating of Buy and set a new price target of $15.00 from $16.00 previously

    11/12/21 6:13:11 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    $CODX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Co-Diagnostics Appoints Wes Lindsey, PhD, MBA as Chief Scientific Officer

    SALT LAKE CITY, July 16, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the appointment of Wes Lindsey, PhD, MBA as the Company's new Chief Scientific Officer ("CSO"). Dr. Lindsey brings more than 20 years' experience in molecular diagnostics. He holds a PhD in Genetics & Molecular Biology from Emory University and an MBA from Georgia State University. Over his career, Dr. Lindsey has led assay development and R&D teams that produced more than a dozen FDA 510(k)

    7/16/26 9:00:00 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Co-Diagnostics Invited to Participate in NPOC Tuberculosis Diagnostics Workshop in Bangkok, Thailand

    Invited by the Stop TB Partnership and the Global Fund to participate as a manufacturer partnerWorkshop brings together national TB programs, researchers, donors, and technical agencies from 21 countries to advance implementation of WHO-recommended near-point-of-care diagnosticsSALT LAKE CITY, July 8, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has been invited to participate as a manufacturer partner in the United Nations Office for Project Services' (UNOPS) Global Implementation Workshop on Near Point of Care (NP

    7/8/26 9:00:00 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Co-Diagnostics Completes Clinical and Analytical Studies in Preparation for FDA 510(k) Submission of Upper Respiratory Point-of-Care Test

    More than 1,400 patients enrolled across 9 clinical sites; analytical performance testing included 27 individual studies and over 10,000 PCR test cup runsAnalytical data to support concurrent 510(k) submission with CLIA Waiver by Application for point-of-care settings, with submission targeted for Q3 2026SALT LAKE CITY, July 1, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the completion of clinical and analytical performance studies for the Co-Dx™ PCR Flu A/B & RSV upper respiratory multiplex test on the Co-Dx PCR Pro® inst

    7/1/26 9:00:00 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    $CODX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Egan Dwight H was granted 4,584 shares and returned $8,279 worth of shares to the company (1,633 units at $5.07), increasing direct ownership by 12% to 27,893 units (SEC Form 4) (withholding tax)

    4 - Co-Diagnostics, Inc. (0001692415) (Issuer)

    5/27/26 4:04:45 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Brown Brian Lee was granted 3,750 shares and returned $6,844 worth of shares to the company (1,350 units at $5.07), increasing direct ownership by 12% to 22,379 units (SEC Form 4) to cover taxes

    4 - Co-Diagnostics, Inc. (0001692415) (Issuer)

    5/27/26 4:04:12 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    President Abbott Richard David was granted 1,890 shares and returned $3,448 worth of shares to the company (680 units at $5.07), increasing direct ownership by 55% to 3,417 units (SEC Form 4) (withholding obligation)

    4 - Co-Diagnostics, Inc. (0001692415) (Issuer)

    5/27/26 4:03:48 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    $CODX
    SEC Filings

    View All

    SEC Form DEF 14A filed by Co-Diagnostics Inc.

    DEF 14A - Co-Diagnostics, Inc. (0001692415) (Filer)

    7/21/26 9:00:24 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    SEC Form PRE 14A filed by Co-Diagnostics Inc.

    PRE 14A - Co-Diagnostics, Inc. (0001692415) (Filer)

    7/9/26 6:18:23 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    SEC Form SCHEDULE 13G filed by Co-Diagnostics Inc.

    SCHEDULE 13G - Co-Diagnostics, Inc. (0001692415) (Subject)

    6/3/26 4:22:01 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    $CODX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Co-Diagnostics Inc. (Amendment)

    SC 13G/A - Co-Diagnostics, Inc. (0001692415) (Subject)

    2/13/24 5:02:32 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Co-Diagnostics Inc. (Amendment)

    SC 13G/A - Co-Diagnostics, Inc. (0001692415) (Subject)

    2/9/22 3:43:31 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Co-Diagnostics, Inc. (Amendment)

    SC 13G/A - Co-Diagnostics, Inc. (0001692415) (Subject)

    7/12/21 8:29:19 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    $CODX
    Financials

    Live finance-specific insights

    View All

    Co-Diagnostics Reports First Quarter 2026 Financial Results

    Advancing Global Commercialization Through CoSara Regulatory Progress and Regional ExpansionExecuting Clinical Strategy with Upper Respiratory Submission Preparation and TB Study InitiationExpanding International Presence and Reinforcing Platform Differentiation Through Partnerships and IPSALT LAKE CITY, May 14, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx," or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced its financial results for the first quarter ended March 31, 2026.

    5/14/26 4:01:00 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Co-Diagnostics Announces First Quarter 2026 Earnings Release Date and Webcast

    SALT LAKE CITY, April 30, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced it will release its first quarter 2026 financial results on Thursday, May 14, 2026, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts. Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations.

    4/30/26 9:00:00 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Co-Diagnostics Reports Full Year 2025 Financial Results

    Advancing Global Commercialization Strategy Through CoSara and CoMira Joint VenturesProgressing Clinical Pipeline and Regulatory Pathways for PCR PlatformStrengthening Technology Leadership with AI Integration and Expanding IP PortfolioSALT LAKE CITY, March 31, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Diagnostics," "Co-Dx," or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced its financial results for the full year ended December 31, 2025. Full Year 2025 Financia

    3/31/26 4:01:00 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    $CODX
    Leadership Updates

    Live Leadership Updates

    View All

    Co-Diagnostics Appoints Wes Lindsey, PhD, MBA as Chief Scientific Officer

    SALT LAKE CITY, July 16, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the appointment of Wes Lindsey, PhD, MBA as the Company's new Chief Scientific Officer ("CSO"). Dr. Lindsey brings more than 20 years' experience in molecular diagnostics. He holds a PhD in Genetics & Molecular Biology from Emory University and an MBA from Georgia State University. Over his career, Dr. Lindsey has led assay development and R&D teams that produced more than a dozen FDA 510(k)

    7/16/26 9:00:00 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Co-Diagnostics, Inc. Appoints New President and Other C-Level Positions

    SALT LAKE CITY, April 4, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that last month the Board of Directors appointed Richard Abbott as President of Co-Diagnostics, Inc., concurrent with the Company naming David Nielsen to be its Chief Operations Officer (COO), Christopher Thurston as its Chief Technology Officer (CTO), and Seth Egan as Chief Commercialization Officer (CCO). Prior to his new role at the Com

    4/4/24 9:30:00 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Co-Diagnostics, Inc. Appoints Chief Regulatory Affairs Officer

    SALT LAKE CITY, Aug. 29, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is pleased to welcome Ivory Chang as the Company's Chief Regulatory Affairs Officer. Ms. Chang's in-depth regulatory affairs experience has included time spent with several notable names in the diagnostics industry, including Roche, Boston Scientific, BD Biosciences, Cepheid, Thermo Fisher Scientific, and more. Her background has i

    8/29/23 9:30:00 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care